Spago Nanomedical AB (publ) (SPAGO.ST)
SEK 0.19
(7.39%)
SEK 0.19
(7.39%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -42.5 Million SEK | -19.68% |
| 2022 | -39.46 Million SEK | -0.7% |
| 2021 | -39.19 Million SEK | -106.69% |
| 2020 | -18.96 Million SEK | 5.86% |
| 2019 | -20.14 Million SEK | -81.59% |
| 2018 | -11.09 Million SEK | -22.08% |
| 2017 | -9.08 Million SEK | -24.35% |
| 2016 | -7.3 Million SEK | 40.87% |
| 2015 | -12.35 Million SEK | -110.33% |
| 2014 | -5.87 Million SEK | -16.48% |
| 2013 | -5.04 Million SEK | -41.61% |
| 2012 | -3.56 Million SEK | -398.18% |
| 2011 | -715 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -9.09 Million SEK | 19.08% |
| 2024 Q2 | -9.69 Million SEK | -6.59% |
| 2023 Q2 | -8.1 Million SEK | 44.61% |
| 2023 Q3 | -7.3 Million SEK | 9.81% |
| 2023 FY | -47.23 Million SEK | -19.68% |
| 2023 Q4 | -11.23 Million SEK | -53.76% |
| 2023 Q1 | -14.62 Million SEK | -29.14% |
| 2022 FY | -39.46 Million SEK | -0.7% |
| 2022 Q1 | -9.9 Million SEK | 12.53% |
| 2022 Q4 | -11.32 Million SEK | -30.87% |
| 2022 Q3 | -8.65 Million SEK | 9.66% |
| 2022 Q2 | -9.58 Million SEK | 3.24% |
| 2021 Q3 | -10.13 Million SEK | 12.96% |
| 2021 Q1 | -6.06 Million SEK | -30.27% |
| 2021 Q4 | -11.32 Million SEK | -11.68% |
| 2021 Q2 | -11.64 Million SEK | -91.92% |
| 2021 FY | -39.19 Million SEK | -106.69% |
| 2020 FY | -18.96 Million SEK | 5.86% |
| 2020 Q1 | -5.05 Million SEK | 15.14% |
| 2020 Q2 | -4.76 Million SEK | 5.74% |
| 2020 Q3 | -4.48 Million SEK | 5.86% |
| 2020 Q4 | -4.65 Million SEK | -3.86% |
| 2019 Q2 | -4.54 Million SEK | 1.43% |
| 2019 Q4 | -5.95 Million SEK | -16.9% |
| 2019 Q3 | -5.09 Million SEK | -12.05% |
| 2019 FY | -20.14 Million SEK | -81.59% |
| 2019 Q1 | -4.61 Million SEK | -39.58% |
| 2018 Q1 | -2.45 Million SEK | 10.95% |
| 2018 Q3 | -2.24 Million SEK | 27.5% |
| 2018 Q4 | -3.3 Million SEK | -47.48% |
| 2018 FY | -11.09 Million SEK | -22.08% |
| 2018 Q2 | -3.09 Million SEK | -25.86% |
| 2017 Q3 | -1.91 Million SEK | 22.51% |
| 2017 Q4 | -2.75 Million SEK | -44.1% |
| 2017 FY | -9.08 Million SEK | -24.35% |
| 2017 Q1 | -1.94 Million SEK | 84.92% |
| 2017 Q2 | -2.47 Million SEK | -27.06% |
| 2016 Q1 | -2.21 Million SEK | 68.35% |
| 2016 FY | -7.3 Million SEK | 40.87% |
| 2016 Q4 | -12.89 Million SEK | -913.76% |
| 2016 Q3 | -1.27 Million SEK | 39.57% |
| 2016 Q2 | -2.1 Million SEK | 4.79% |
| 2015 Q3 | -1.32 Million SEK | 31.47% |
| 2015 Q2 | -1.93 Million SEK | 8.34% |
| 2015 Q1 | -2.11 Million SEK | -2.58% |
| 2015 Q4 | -6.98 Million SEK | -426.77% |
| 2015 FY | -12.35 Million SEK | -110.33% |
| 2014 FY | -5.87 Million SEK | -16.48% |
| 2014 Q4 | -2.05 Million SEK | -135.74% |
| 2014 Q3 | -873 Thousand SEK | 51.07% |
| 2014 Q2 | -1.78 Million SEK | -53.79% |
| 2014 Q1 | -1.16 Million SEK | 55.06% |
| 2013 Q1 | -1.28 Million SEK | -10.93% |
| 2013 Q3 | -1.03 Million SEK | -675.37% |
| 2013 Q4 | -2.58 Million SEK | -148.41% |
| 2013 FY | -5.04 Million SEK | -41.61% |
| 2013 Q2 | -134 Thousand SEK | 89.6% |
| 2012 FY | -3.56 Million SEK | -398.18% |
| 2012 Q4 | -1.16 Million SEK | -54.73% |
| 2012 Q2 | -15 Thousand SEK | 98.2% |
| 2012 Q3 | -751 Thousand SEK | -4906.67% |
| 2012 Q1 | -834 Thousand SEK | 0.0% |
| 2011 FY | -715 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 82.929% |
| Ziccum AB (publ) | -21.56 Million SEK | -97.147% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -159.161% |
| BioArctic AB (publ) | 252.64 Million SEK | 116.824% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -4930.178% |
| Mendus AB (publ) | -100.65 Million SEK | 57.769% |
| Genovis AB (publ.) | 54.22 Million SEK | 178.388% |
| Intervacc AB (publ) | -93.57 Million SEK | 54.578% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -174.014% |
| Active Biotech AB (publ) | -46.48 Million SEK | 8.56% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 336.021% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 23.3% |
| Aptahem AB (publ) | -10.1 Million SEK | -320.643% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 86.779% |
| Kancera AB (publ) | -65.04 Million SEK | 34.65% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 68.425% |
| Fluicell AB (publ) | -26.87 Million SEK | -58.135% |
| Saniona AB (publ) | -81.06 Million SEK | 47.567% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -243.586% |
| Biovica International AB (publ) | -126.07 Million SEK | 66.285% |
| AcouSort AB (publ) | -17.48 Million SEK | -143.066% |
| Xintela AB (publ) | -57.23 Million SEK | 25.74% |
| Abliva AB (publ) | -96.54 Million SEK | 55.975% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 86.913% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -1112.696% |
| OncoZenge AB (publ) | -15.9 Million SEK | -167.293% |
| Amniotics AB (publ) | -29.07 Million SEK | -46.201% |
| 2cureX AB (publ) | -36.36 Million SEK | -16.891% |
| CombiGene AB (publ) | -36.3 Million SEK | -17.077% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -190.335% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 88.942% |
| Camurus AB (publ) | 532.35 Million SEK | 107.984% |
| Corline Biomedical AB | -1.78 Million SEK | -2277.237% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 76.486% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -1.972% |
| I-Tech AB | 24.43 Million SEK | 273.951% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 94.609% |
| Cyxone AB (publ) | -21.66 Million SEK | -96.228% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 59.888% |
| Biosergen AB | -27.26 Million SEK | -55.896% |
| Cantargia AB (publ) | -290.01 Million SEK | 85.344% |
| NextCell Pharma AB | -43.17 Million SEK | 1.545% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 76.486% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -148.621% |
| Nanologica AB (publ) | -69.96 Million SEK | 39.246% |
| SynAct Pharma AB | -224.49 Million SEK | 81.066% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 3.783% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -77.442% |
| LIDDS AB (publ) | -40.67 Million SEK | -4.502% |
| Lipum AB (publ) | -37.25 Million SEK | -14.095% |
| BioInvent International AB (publ) | -369.94 Million SEK | 88.51% |
| Alzinova AB (publ) | -16.52 Million SEK | -157.263% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 83.229% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -564.842% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 63.063% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -111.058% |
| Simris Alg AB (publ) | -36.63 Million SEK | -16.023% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 71.0% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 86.308% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 61.678% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -267.5% |